Pharmacokinetic study reveals reliable plasma exposure but poor cerebrospinal fluid predictability in neurocritical care, suggesting challenges in dosing ceftriaxone for ventriculitis.
BACKGROUND: Patient outcomes during ventriculitis may be improved by antibiotic dose optimisation strategies that increase the achievement of therapeutic concentrations at the infection site. We performed a population pharmacokinetic (PK) study in neurocritical care patients to define ceftriaxone dosing regimens required to achieve effective cerebrospinal fluid (CSF) exposures. METHODS: ), were performed. RESULTS: in plasma for an MIC of 1 mg/L, respectively. The model was unable to accurately predict ceftriaxone concentrations in CSF, precluding CSF dosing simulations. CONCLUSIONS: High attainment of plasma target exposures was achieved with higher than standard dosing. Dosing recommendations to optimise targeted CSF ceftriaxone exposures for treatment of ventriculitis could not be made given inadequate model predictability.
No takes yet. Share an insight, caveat, or question.
Kumta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: